| 0.6459 -0.209 (-24.4%) | 01-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.31  |
1-year : | 1.69 |
| Resists | First : | 1.12 |
Second : | 1.45 |
| Pivot price | 0.87 |
|||
| Supports | First : | 0.59 |
Second : | 0.49 |
| MAs | MA(5) : | 0.84 |
MA(20) : | 0.86 |
| MA(100) : | 1.23 |
MA(250) : | 4.53 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 26.5 |
D(3) : | 53.3 |
| RSI | RSI(14): 25.6 |
|||
| 52-week | High : | 14.1 | Low : | 0.59 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ REVB ] has closed below the lower bollinger band by 31.6%. Bollinger Bands are 42.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.45 - 1.46 | 1.46 - 1.47 |
| Low: | 0.59 - 0.59 | 0.59 - 0.6 |
| Close: | 0.62 - 0.63 | 0.63 - 0.64 |
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
Fri, 23 Jan 2026
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) - knoxnews.com
Fri, 23 Jan 2026
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds - thenewstribune.com
Fri, 23 Jan 2026
Revelation Biosciences trades new 5-year warrants for $11M cash - Stock Titan
Fri, 23 Jan 2026
Revelation Biosciences Gains Momentum as FDA Agreement Sparks Hope - StocksToTrade
Fri, 23 Jan 2026
Revelation Biosciences (REVB) Secures FDA Agreement for Gemini Drug's Clinical Trial Pathway - Intellectia AI
Fri, 23 Jan 2026
Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours? - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 25.3 (%) |
| Held by Institutions | 11.8 (%) |
| Shares Short | 37 (K) |
| Shares Short P.Month | 10 (K) |
| EPS | 81.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.06 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -52.7 % |
| Return on Equity (ttm) | -118.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0.2 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|